8+2+1: EU data and market protection formula

The formula comes from Article 10(1) of Directive 2001/83/EC and Article 14(11) of Regulation (EC) No 726/2004, which harmonised protection periods for reference products authorised from late 2005. For eight years after the first EU authorisation of a reference product, no generic, hybrid or biosimilar application can rely on its preclinical and clinical data. For a further two years the generic can be authorised but not placed on the market. The extra year is granted when, during the first eight years, the holder obtains a new therapeutic indication that is held to bring a significant clinical benefit compared with existing therapies, so the maximum is eleven years.

The clock starts with the first authorisation anywhere in the EU, whether national or central, and it runs once for the whole global marketing authorisation. New strengths, forms, routes and most line extensions fall inside it and do not restart the period. Products first authorised before the 2005 cut-off still follow the older six or ten year national periods, which is why a dossier review of the reference product's authorisation history is the first step in any generic plan.

What goes wrong: counting from a later national approval rather than the first EU authorisation, assuming the eleventh year applies before checking that the indication was both authorised inside the eight-year window and accepted as a significant benefit, and forgetting that the extra year also delays market entry in the Member States that have not published the generic entry date. Teams also confuse regulatory protection with patent and SPC expiry, which run independently and often later. Timing generic filings without the exact reference dates can mean a submission that is rejected as premature, or a launch that is months later than it needed to be.

Under the new pharma package (not yet in force), the automatic formula goes. Baseline protection becomes eight years of data protection plus one year of market protection, with one extra year for addressing an unmet medical need or for a qualifying new active substance with comparator trials and EU-first filing, and one more for a significant new indication, capped at eleven years. The new periods apply to reference products whose applications are filed after the rules apply, and a Member State may ask the holder to supply its market, with market protection lapsing there if the product is not made available within three years; see exclusivity changes.